ANSTO annual report 2004-05
| dc.contributor.author | The Australian Nuclear Science and Technology Organisation | en_AU |
| dc.date.accessioned | 2009-10-23 | en_AU |
| dc.date.accessioned | 2010-04-30T04:08:42Z | en_AU |
| dc.date.available | 2009-10-23 | en_AU |
| dc.date.available | 2010-04-30T04:08:42Z | en_AU |
| dc.date.issued | 2005 | en_AU |
| dc.description.abstract | The Australian Nuclear Science and Technology Organisation (ANSTO) is Australia’s national nuclear research and development organisation and the centre of Australian nuclear expertise. With approximately 860 staff, ANSTO is responsible for delivering specialised advice, scientific services and products to government, industry, academia and other research organisations. We do so through the development of new knowledge, the delivery of quality services and the provision of support for business opportunities. ANSTO’s nuclear infrastructure includes the research reactor HIFAR (High Flux Australian Reactor), particle accelerators, radiopharmaceutical production facilities, and a range of other unique research facilities. HIFAR is Australia’s only nuclear reactor. It is used to produce radioactive products for use in medicine and industry, as a source of neutron beams for scientific research and to irradiate silicon for semiconductor applications. A replacement for HIFAR, OPAL – the Open Pool Australian Light-water reactor – is in its final stages of construction. ANSTO also operates the National Medical Cyclotron, an accelerator facility used to produce certain short-lived radioisotopes for nuclear medicine procedures. It is located in the grounds of the Royal Prince Alfred Hospital in Camperdown. ANSTO also manages access to overseas synchrotron facilities for Australian scientists. ANSTO’s main site is located 40 km south west of Sydney’s central business district, occupies 70 hectares and is surrounded by a 1.6 km buffer zone. ANSTO’s general purpose is prescribed by the Australian Nuclear Science and Technology Organisation Act 1987 and is translated into action through corporate drivers of vision, mission and strategic goals. | en_AU |
| dc.identifier.govdoc | 3 | en_AU |
| dc.identifier.issn | 1031-6655 | en_AU |
| dc.identifier.uri | http://apo.ansto.gov.au/dspace/handle/10238/2076 | en_AU |
| dc.language.iso | en | en_AU |
| dc.publisher | Australian Nuclear Science and Technology Organisation | en_AU |
| dc.relation.ispartofseries | Annual Report | en_AU |
| dc.subject | ANSTO | en_AU |
| dc.subject | Progress report | en_AU |
| dc.subject | OPAL Reactor | en_AU |
| dc.subject | HIFAR Reactor | en_AU |
| dc.subject | Radiopharmaceuticals | en_AU |
| dc.subject | Australia | en_AU |
| dc.title | ANSTO annual report 2004-05 | en_AU |
| dc.type | External Report | en_AU |